Back to top
more

Zoetis (ZTS)

(Delayed Data from NYSE)

$75.02 USD

75.02
3,972,735

-2.50 (-3.22%)

Updated Aug 27, 2026 04:03 PM ET

After-Market: $75.13 +0.11 (0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (150 out of 247)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised

by Zacks Equity Research

Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.

Zacks Equity Research

Zoetis (ZTS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Zoetis (ZTS) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) delivered earnings and revenue surprises of +8.64% and +2.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.

Zacks Equity Research

BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of +400.00% and +9.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect

by Zacks Equity Research

ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.

Zacks Equity Research

Countdown to Zoetis (ZTS) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Besides Wall Street's top-and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

Zacks Equity Research

Here's Why Zoetis (ZTS) Fell More Than Broader Market

by Zacks Equity Research

In the latest trading session, Zoetis (ZTS) closed at $148.81, marking a -1.46% move from the previous day.

Zacks Equity Research

Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.